Diabetes Monitoring: Which Tests and How Often
Content last reviewed 2026-09-12 · Educational information — not medical advice
Quick answer
Established diabetes runs a defined lab calendar: A1C quarterly-if-unstable/half-yearly-if-stable, annual urine-albumin + eGFR + lipids + eye exams, plus foot checks — each test exists because its complication arrives silently otherwise.
The monitoring calendar
| Test | Frequency | Guards against |
|---|---|---|
| HbA1c | quarterly if adjusting/uncontrolled; 6-monthly stable | cumulative sugar damage |
| Urine albumin (ACR) | annual | earliest kidney-damage signal |
| Serum creatinine/eGFR | annual minimum | filtration trajectory, med dosing |
| Lipid panel | annual | cardiac-risk management (leading killer) |
| Dilated eye exam | annual | retinopathy (silent until vision loss) |
| Foot exam + monofilament | every visit ideally | neuropathy/amputation cascade |
| B12 | periodically on metformin | metformin-drain deficiency |
Targets individualize
A1C <7% general adult default; looser (<8%) for hypoglycemia-prone/limited-life-expectancy elders; tighter (<6.5%) for early-disease motivated patients if achievable without lows. BP <130/80, statin-therapy nearly universal, SGLT2/GLP-1 agents now recommended for kidney/heart protection independent of sugar effects.
Self-monitoring versus laboratory monitoring
Fingerstick/CGM glucose handles DAY-TO-DAY steering; A1C handles QUARTERLY strategy verification. CGM adoption transformed management granularity — time-in-range metrics supplement A1C meaningfully now, particularly catching hypoglycemia A1C averages conceal.
Complication screening saves specific things
Eye exams prevent blindness through laser/anti-VEGF timing; urine-albumin triggers kidney-preserving drug classes; foot exams prevent the ulcer-amputation cascade. Each screening maps to a preventable endpoint — skipping them forfeits named protections.
Order this test online
Direct-access laboratory testing — no appointment or doctor visit required. Results delivered as secure PDFs.
We may earn a commission when you order through partner links. Educational content only — never a substitute for professional medical advice.
Related guides
Frequently asked questions
Type 2 remission — do I still need monitoring?
Yes — remission maintenance itself requires surveillance, and relapse risk persists indefinitely; annual minimums continue.
Does metformin alone require all this?
Metformin-monotherapy patients with perfect control still earn annual complication screens — the disease, not the drug, sets calendar.